1
|
Sidorenko GV, Miroslavov AE, Tyupina MY. Technetium(I) carbonyl complexes for nuclear medicine: Coordination-chemical aspect. Coord Chem Rev 2023. [DOI: 10.1016/j.ccr.2022.214911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Collantes M, Vairo C, Erhard Á, Navas C, Villullas S, Ecay M, Pareja F, Quincoces G, Gainza G, Peñuelas I. Preclinical safety of negatively charged microspheres (NCMs): optimization of radiolabeling for in vivo and ex vivo biodistribution studies after topical administration on full-thickness wounds in a rat model. Eur J Pharm Biopharm 2022; 177:61-67. [PMID: 35697288 DOI: 10.1016/j.ejpb.2022.06.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 06/01/2022] [Accepted: 06/04/2022] [Indexed: 11/15/2022]
Abstract
Negatively charged microspheres (NCMs) are postulated as a new form of treatment for chronic wounds. Despite the efficacy shown at clinical level, more studies are required to demonstrate their safety and local effect. The objective of the work was to confirm the lack of NCM systemic absorption performing a biodistribution study of the NCMs in an open wound rat animal model. To this end, radiolabeling of NCMs with technetium-99m was optimized and biodistribution studies were performed by in vivo SPEC/CT imaging and ex vivo counting during 24 h after topical administration. The studies were performed on animals treated with a single or repeated dose to study the effect of macrophages during a prolonged treatment. NCM radiolabeling was achieved in a simple, efficient and stable manner with high yield. SPECT/CT images showed that almost all NCMs (about 85 %) remained on the wound for 24 h either after single or multiple administrations. Ex vivo biodistribution studies confirmed that there was no accumulation of NCMs in any organ or tissue except in the wound area, suggesting a lack of absorption. In conclusion, NCMs can be considered safe as local wound treatment since they remain at the administration area.
Collapse
Affiliation(s)
- María Collantes
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain
| | - Claudia Vairo
- BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510, Miñano, Spain
| | - Álvaro Erhard
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Cristina Navas
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Silvia Villullas
- BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510, Miñano, Spain
| | - Margarita Ecay
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Félix Pareja
- Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain
| | - Gemma Quincoces
- RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain
| | - Garazi Gainza
- BioKeralty Research Institute AIE, Albert Einstein, 25-E3, 01510, Miñano, Spain.
| | - Iván Peñuelas
- Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; RADIOMIN Research Group, Radiopharmacy Unit, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Nuclear Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31080, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain
| |
Collapse
|
3
|
Lasa-Saracíbar B, El Moukhtari SH, Tsotakos T, Xanthopoulos S, Loudos G, Bouziotis P, Blanco-Prieto MJ. In vivo biodistribution of edelfosine-loaded lipid nanoparticles radiolabeled with Technetium-99m: comparison of administration routes in mice. Eur J Pharm Biopharm 2022; 175:1-6. [DOI: 10.1016/j.ejpb.2022.04.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 04/08/2022] [Accepted: 04/19/2022] [Indexed: 02/07/2023]
|
4
|
De Silva L, Fu JY, Htar TT, Wan Kamal WHB, Kasbollah A, Muniyandy S, Chuah LH. Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging. Front Pharmacol 2022; 12:778396. [PMID: 35069200 PMCID: PMC8777053 DOI: 10.3389/fphar.2021.778396] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 12/10/2021] [Indexed: 11/13/2022] Open
Abstract
The purpose of this work was to study the biodistribution of niosomes in tumor-implanted BALB/c mice using gamma scintigraphy. Niosomes were first formulated and characterized, then radiolabeled with Technetium-99 m (99mTc). The biodistribution of 99mTc-labeled niosomes was evaluated in tumor-bearing mice through intravenous injection and imaged with gamma scintigraphy. The labeled complexes possessed high radiolabeling efficiency (98.08%) and were stable in vitro (>80% after 8 h). Scintigraphic imaging showed negligible accumulation in the stomach and thyroid, indicating minimal leaching of the radiolabel in vivo. Radioactivity was found mainly in the liver, spleen and kidneys. Tumor-to-muscle ratio indicated a higher specificity of the formulation for the tumor area. Overall, the formulated niosomes are stable both in vitro and in vivo, and show preferential tumor accumulation.
Collapse
Affiliation(s)
- Leanne De Silva
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia
| | - Ju-Yen Fu
- Nutrition Unit, Malaysian Palm Oil Board, Bandar Baru Bangi, Malaysia
| | - Thet Thet Htar
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia
| | | | - Azahari Kasbollah
- Medical Technology Division, Malaysian Nuclear Agency, Bangi, Malaysia
| | - Saravanan Muniyandy
- Department of Pharmacy, Fatima College of Health Sciences, Al Ain, United Arab Emirates
| | - Lay-Hong Chuah
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia
| |
Collapse
|
5
|
Mamai M, Giasafaki D, Salvanou EA, Charalambopoulou G, Steriotis T, Bouziotis P. Biodistribution of Mesoporous Carbon Nanoparticles via Technetium-99m Radiolabelling after Oral Administration to Mice. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:3260. [PMID: 34947611 PMCID: PMC8703805 DOI: 10.3390/nano11123260] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 11/25/2021] [Accepted: 11/26/2021] [Indexed: 02/06/2023]
Abstract
The use of ordered mesoporous matrices, and in particular carbon-based mesoporous nanoparticles has shown great potential towards enhancing the bioavailability of orally administered drugs. Nevertheless, elucidation of the in vivo absorption, distribution, and excretion of such carriers is essential for understanding their behaviour, and radiolabelling provides a very useful way to track their occurrence inside the body. In this work, uniform spherical CMK-1-type ordered mesoporous carbon nanoparticles have been radiolabelled with Technetium-99m (99mTc) and traced after oral administration to mice. Ex vivo biodistribution studies showed that the radiolabelled nanoparticles accumulated almost exclusively in the gastrointestinal tract; complete elimination of the radiotracer was observed within 24 h after administration, with practically no uptake into other main organs. These findings along with the results from in vitro stability studies indicate that the spherical carbon nanoparticles examined could be safely used as drug carriers with minimal side effects, but also support the great value of radiolabelling methods for monitoring the particles' behaviour in vivo.
Collapse
Affiliation(s)
- Maria Mamai
- Institute of Nuclear & Radiological Sciences and Technology, Energy & Safety, National Centre for Scientific Research “Demokritos”, 15341 Athens, Greece; (M.M.); (E.-A.S.)
- Institute of Nanoscience & Nanotechnology, National Centre for Scientific Research “Demokritos”, 15341 Athens, Greece; (D.G.); (T.S.)
| | - Dimitra Giasafaki
- Institute of Nanoscience & Nanotechnology, National Centre for Scientific Research “Demokritos”, 15341 Athens, Greece; (D.G.); (T.S.)
| | - Evangelia-Alexandra Salvanou
- Institute of Nuclear & Radiological Sciences and Technology, Energy & Safety, National Centre for Scientific Research “Demokritos”, 15341 Athens, Greece; (M.M.); (E.-A.S.)
| | - Georgia Charalambopoulou
- Institute of Nuclear & Radiological Sciences and Technology, Energy & Safety, National Centre for Scientific Research “Demokritos”, 15341 Athens, Greece; (M.M.); (E.-A.S.)
| | - Theodore Steriotis
- Institute of Nanoscience & Nanotechnology, National Centre for Scientific Research “Demokritos”, 15341 Athens, Greece; (D.G.); (T.S.)
| | - Penelope Bouziotis
- Institute of Nuclear & Radiological Sciences and Technology, Energy & Safety, National Centre for Scientific Research “Demokritos”, 15341 Athens, Greece; (M.M.); (E.-A.S.)
| |
Collapse
|
6
|
Pandey V, Haider T, Chandak AR, Chakraborty A, Banerjee S, Soni V. Technetium labeled doxorubicin loaded silk fibroin nanoparticles: Optimization, characterization and in vitro evaluation. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101539] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
7
|
De Silva L, Fu JY, Htar TT, Muniyandy S, Kasbollah A, Wan Kamal WHB, Chuah LH. Characterization, optimization, and in vitro evaluation of Technetium-99m-labeled niosomes. Int J Nanomedicine 2019; 14:1101-1117. [PMID: 30863048 PMCID: PMC6391155 DOI: 10.2147/ijn.s184912] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Background and purpose Niosomes are nonionic surfactant-based vesicles that exhibit certain unique features which make them favorable nanocarriers for sustained drug delivery in cancer therapy. Biodistribution studies are critical in assessing if a nanocarrier system has preferential accumulation in a tumor by enhanced permeability and retention effect. Radiolabeling of nanocarriers with radioisotopes such as Technetium-99m (99mTc) will allow for the tracking of the nanocarrier noninvasively via nuclear imaging. The purpose of this study was to formulate, characterize, and optimize 99mTc-labeled niosomes. Methods Niosomes were prepared from a mixture of sorbitan monostearate 60, cholesterol, and synthesized D-α-tocopherol polyethylene glycol 1000 succinate-diethylenetriaminepentaacetic acid (synthesis confirmed by 1H and 13C nuclear magnetic resonance spectroscopy). Niosomes were radiolabeled by surface chelation with reduced 99mTc. Parameters affecting the radiolabeling efficiency such as concentration of stannous chloride (SnCl2·H2O), pH, and incubation time were evaluated. In vitro stability of radiolabeled niosomes was studied in 0.9% saline and human serum at 37°C for up to 8 hours. Results Niosomes had an average particle size of 110.2±0.7 nm, polydispersity index of 0.229±0.008, and zeta potential of −64.8±1.2 mV. Experimental data revealed that 30 µg/mL of SnCl2·H2O was the optimal concentration of reducing agent required for the radiolabeling process. The pH and incubation time required to obtain high radiolabeling efficiency was pH 5 and 15 minutes, respectively. 99mTc-labeled niosomes exhibited high radiolabeling efficiency (>90%) and showed good in vitro stability for up to 8 hours. Conclusion To our knowledge, this is the first study published on the surface chelation of niosomes with 99mTc. The formulated 99mTc-labeled niosomes possessed high radiolabeling efficacy, good stability in vitro, and show good promise for potential use in nuclear imaging in the future.
Collapse
Affiliation(s)
- Leanne De Silva
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia,
| | - Ju-Yen Fu
- Nutrition Unit, Malaysian Palm Oil Board, Bandar Baru Bangi, Selangor, Malaysia,
| | - Thet Thet Htar
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia,
| | - Saravanan Muniyandy
- Department of Pharmacy, Fatima College of Health Sciences, Al Ain, United Arab Emirates
| | - Azahari Kasbollah
- Medical Technology Division, Malaysian Nuclear Agency, Bangi, Selangor, Malaysia
| | | | - Lay-Hong Chuah
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia, .,Advanced Engineering Platform, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia,
| |
Collapse
|
8
|
Georgiou M, Fysikopoulos E, Mikropoulos K, Fragogeorgi E, Loudos G. Characterization of "γ-Eye": a Low-Cost Benchtop Mouse-Sized Gamma Camera for Dynamic and Static Imaging Studies. Mol Imaging Biol 2018; 19:398-407. [PMID: 27730469 DOI: 10.1007/s11307-016-1011-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
PURPOSE Several preclinical imaging systems are commercially available, but their purchase and maintenance costs make them unaffordable for the majority of small- and medium-sized groups. Taking into account the needs of average users, we developed "γ-eye", a mouse-sized, benchtop γ-camera suitable for in vivo scintigraphic imaging. PROCEDURES The γ-eye is based on two position-sensitive photomultiplier tubes, coupled to a CsI(Na) pixelated scintillator and a low-energy lead collimator with parallel hexagonal holes. RESULTS The spatial resolution of the system is 2 mm at 0 mm. The energy resolution is 26 % at 140 keV and the maximum recorded sensitivity 210 cps/MBq. The system was evaluated in a proof-of-concept animal study, using three different clinical Tc-99m-labeled radiopharmaceuticals. Phantom and animal studies demonstrate its ability to provide semiquantitative results even for short scans. CONCLUSIONS Systems' performance, dimensions, and cost make γ-eye a unique solution for efficient whole-body mouse nuclear imaging.
Collapse
Affiliation(s)
| | | | - Konstantinos Mikropoulos
- Department of Biomedical Engineering, Technological Educational Institute of Athens, Athens, Greece
| | - Eirini Fragogeorgi
- National Centre for Scientific Research NCSR "Demokritos", Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety, Athens, Greece
| | - George Loudos
- Department of Biomedical Engineering, Technological Educational Institute of Athens, Athens, Greece.,National Centre for Scientific Research NCSR "Demokritos", Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety, Athens, Greece
| |
Collapse
|
9
|
Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel LL, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K, Grenacher L, Reese T, Kreuter J, Jiménez-González M. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release 2015; 214:76-84. [PMID: 26192099 DOI: 10.1016/j.jconrel.2015.07.017] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 07/14/2015] [Accepted: 07/15/2015] [Indexed: 01/15/2023]
Abstract
Highly aggressive cancer types such as pancreatic cancer possess a mortality rate of up to 80% within the first 6months after diagnosis. To reduce this high mortality rate, more sensitive diagnostic tools allowing an early stage medical imaging of even very small tumours are needed. For this purpose, magnetic, biodegradable nanoparticles prepared using recombinant human serum albumin (rHSA) and incorporated iron oxide (maghemite, γ-Fe2O3) nanoparticles were developed. Galectin-1 has been chosen as target receptor as this protein is upregulated in pancreatic cancer and its precursor lesions but not in healthy pancreatic tissue nor in pancreatitis. Tissue plasminogen activator derived peptides (t-PA-ligands), that have a high affinity to galectin-1 have been chosen as target moieties and were covalently attached onto the nanoparticle surface. Improved targeting and imaging properties were shown in mice using single photon emission computed tomography-computer tomography (SPECT-CT), a handheld gamma camera, and magnetic resonance imaging (MRI).
Collapse
Affiliation(s)
- I Rosenberger
- Institute of Pharmaceutical Technology, Biocenter Niederursel, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany; Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria
| | - A Strauss
- Department of Diagnostic Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - S Dobiasch
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - C Weis
- Department of Diagnostic Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - S Szanyi
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - L Gil-Iceta
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - E Alonso
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - M González Esparza
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - V Gómez-Vallejo
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - B Szczupak
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - S Plaza-García
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - S Mirzaei
- Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria
| | - L L Israel
- Department of Chemistry & Institute of Nanotechnology & Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel
| | - S Bianchessi
- Fondazione Filarete, Viale Ortles 22/4, 20139 Milano, Italy
| | - E Scanziani
- Fondazione Filarete, Viale Ortles 22/4, 20139 Milano, Italy
| | - J-P Lellouche
- Department of Chemistry & Institute of Nanotechnology & Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel
| | - P Knoll
- Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria
| | - J Werner
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany; Department of General-, Visceral-, Transplantation-, Vascular- and Thorax-Surgery LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - K Felix
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - L Grenacher
- Department of Diagnostic Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - T Reese
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - J Kreuter
- Institute of Pharmaceutical Technology, Biocenter Niederursel, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany.
| | - M Jiménez-González
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| |
Collapse
|